Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare Conference

  Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare
  Conference

         – CEO to Provide Business and Development Program Updates –

Citi Global Healthcare Conference 2013

Business Wire

DUBLIN, Ohio -- February 19, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that Dr.
Mark Pykett, President and Chief Executive Officer, will participate at the
Citi 2013 Global Healthcare Conference on February 25-27, 2013 at the Hilton
New York Hotel in New York City. Dr. Pykett will provide an update of the
Company and its development programs on Tuesday, February 26, 2013 at 11:05 AM
EST.

Investors and the public are invited to listen to a live webcast of Dr.
Pykett’s presentation at
http://www.veracast.com/webcasts/citigroup/healthcare2013/89210684.cfm.
Following the conference, the webcast will be archived for approximately 30
days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.

Contact:

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO
 
Press spacebar to pause and continue. Press esc to stop.